ArticleArchives of osteoporosis2026
Fragility fractures and risk factors in a peritoneal dialysis setting.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dialysis patients have poorly characterized fracture risk. In this retrospective cohort of 325 patients, fragility fractures were frequent, mainly asymptomatic vertebral fractures. Fracture risk is independently associated with prior fractures and vascular calcification but FRAX® underestimates fracture risk, underscoring the need for improved assessment strategies tailored to peritoneal dialysis patients. PURPOSE: Data on fracture incidence, risk factors, and fracture risk assessment tools in patients treated with peritoneal dialysis (PD) remain limited. We aimed to evaluate the prevalence, incidence, and determinants of fragility fractures in PD patients and to assess the performance of the Fracture Risk Assessment Tool (FRAX®).
methodsRetrospective single-center cohort study including adult patients receiving PD for ≥ 12 months. Fragility fractures occurring during PD follow-up were identified through clinical records and review of spine radiographs. Vascular calcification was assessed using the Adragão vascular calcification score (VCS). FRAX® probabilities for fracture risk were calculated without bone mineral density. Logistic regression was used to identify independent predictors of fractures, and receiver operating characteristic (ROC) curves evaluated FRAX® performance.
resultsAmong 325 patients receiving PD (mean age 53 ± 8 years, 57% male), 32 (9.8%) fragility fractures were identified, and most were asymptomatic vertebral fractures (n = 23, 7.1%). In multivariable analysis, previous fracture history (OR 4.85, 95% CI 1.22-19.27) and higher VCS (OR 2.10, 95% CI 1.10-4.03) were independently associated with fracture occurrence. FRAX® showed modest discriminatory ability for any fragility fracture (AUC 0.69) and very low sensitivity at standard intervention thresholds, even when CKD was classified as secondary osteoporosis.
conclusionPatients treated with PD experience a high burden of fragility fractures, largely driven by unrecognized vertebral fractures. Fracture risk is independently associated with prior fractures and vascular calcification. FRAX® underestimates fracture risk in this population, underscoring the need for improved fracture risk assessment strategies tailored to PD patients.
Indexed as
Identifiers
42658370What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.